| Entry |
|
|---|
| Name |
IGF2-overexpression to PI3K signaling pathway
|
|---|
| Definition |
IGF2* -> IGF1R -> PI3K -> PIP3 -> AKT -> MTOR -> S6K |
|---|
| Expanded |
3481v1 -> 3480 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475 -> (6198,6199) |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
| H00048 | Hepatocellular carcinoma |
|
|---|
| Gene |
| 3481 | IGF2; insulin like growth factor 2 |
| 3480 | IGF1R; insulin like growth factor 1 receptor |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 2475 | MTOR; mechanistic target of rapamycin |
| 6198 | RPS6KB1; ribosomal protein S6 kinase B1 |
| 6199 | RPS6KB2; ribosomal protein S6 kinase B2 |
|
|---|
| Variant |
3481v1 (IGF2*) IGF2 overexpression
|
|---|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
|---|
| Reference |
|
|---|
| Authors |
Whittaker S, Marais R, Zhu AX |
|---|
| Title |
The role of signaling pathways in the development and treatment of hepatocellular carcinoma. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. |
|---|
| Title |
Genomics and signaling pathways in hepatocellular carcinoma. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Kudo M |
|---|
| Title |
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM |
|---|
| Title |
Pathogenesis of hepatocellular carcinoma and molecular therapies. |
|---|
| Journal |
|
|---|